The President of the Government of Spain, Pedro Sánchez, received Moderna's Vice-President for Europe, the East and Africa, Dan Staner, the company's Vice-President for Production, Nicholar Chornet, and the General Manager for Spain and Portugal, Juan Carlos Gil.
During the meeting, which was also attended by the Minister for Health, Carolina Darias, and the Secretary General for Economic Affairs and G-20, Manuel de la Rocha, the head of the Executive valued the pharmaceutical company's commitment to Spain to promote messenger RNA technology in Europe.
Moderna acknowledged the government's support in making Spain a benchmark for pharmaceutical innovation. Staner has announced a new Moderna investment in Spain worth more than 500 million euros (over 520 million USD). The company plans to build a quality testing laboratory for messenger RNA vaccines. Moderna is currently working in collaboration with Rovi on a messenger RNA vaccine production plant in Granada and another in San Sebastián de los Reyes (Madrid).
Pedro Sánchez has highlighted the Government of Spain's support for the pharmaceutical sector and R&D&I in recent years and highlighted both the fact that the budget of the Ministry of Science and Innovation has doubled to over 3,800 million euros from 2020 to 2022, and measures such as the Science Law.
The Chief Executive also stressed that the sector is one of the priorities within the Recovery Plan, highlighting the Strategic Project for Economic Recovery and Transformation (PERTE) of Vanguard Healthcare
, which aims to mobilize 1.5 billion euros in public and private investment.
---
UNOFFICIAL TRANSLATION
---
Original statement from La Moncloa (Spanish Presidency)